P192 | PERSISTENT CYTOKINE RELEASE SYNDROME IN PATIENTS RECEIVING BISPECIFIC ANTIBODY THERAPY FOR MULTIPLE MYELOMA: A CASE SERIES
Bispecific antibodies such as Talquetamab have shown efficacy in relapsed/refractory multiple myeloma (RRMM), with cytokine release syndrome (CRS) being a common early toxicity. However, data on persistent or recurrent CRS during ongoing therapy are limited. We report three cases of RRMM patients tr...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Ferrata Storti Foundation
2025-09-01
|
| Seri Bilgileri: | Haematologica |
| Online Erişim: | https://haematologica.org/article/view/12389 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|